Vanguard Group Inc. Has $334.13 Million Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Vanguard Group Inc. has reduced its stake in ADMA Biologics by 7.5%, now holding approximately 16.84 million shares valued at $334 million.
• ADMA Biologics reported earnings of $0.15 per share for the last quarter, beating expectations, with revenue of nearly $122 million, a 13.8% increase year-over-year.
• Insider trading indicated a decrease in ownership as directors sold a combined total of 30,000 shares recently, reflecting changes in confidence among company executives.

Vanguard Group Inc. lessened its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 7.5% in the first quarter, according to its most recent filing with the SEC. The firm owned 16,841,449 shares of the biotechnology company's stock after selling 1,357,347 shares during the quarter. Vanguard Group Inc. owned about 7.09% of ADMA Biologics worth $334,134,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. B Group Inc. acquired a new stake in shares of ADMA Biologics during the fourth quarter worth $39,231,000. Raymond James Financial Inc. acquired a new stake in shares of ADMA Biologics during the fourth quarter worth $19,076,000. Dimensional Fund Advisors LP raised its position in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after purchasing an additional 643,661 shares during the period. Man Group plc raised its position in shares of ADMA Biologics by 305.5% during the fourth quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock worth $12,782,000 after purchasing an additional 561,507 shares during the period. Finally, Tang Capital Management LLC acquired a new stake in shares of ADMA Biologics during the fourth quarter worth $9,432,000. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Down 1.2%

NASDAQ:ADMA traded down $0.20 during trading hours on Thursday, hitting $17.10. 1,902,779 shares of the company's stock traded hands, compared to its average volume of 3,440,492. The firm has a market cap of $4.08 billion, a P/E ratio of 19.88 and a beta of 0.38. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. The stock's fifty day moving average price is $17.97 and its two-hundred day moving average price is $18.87.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.ADMA Biologics's quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.13 earnings per share. On average, research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 455,621 shares of company stock worth $9,461,633. 3.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ADMA. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to MarketBeat, ADMA Biologics presently has a consensus rating of "Buy" and a consensus target price of $27.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.